Teva Gets Canadian Rituximab Nod, But Barriers May Remain

 
• By Aidan Fry
  
Patent_Keyboard
Teva holds approval in Canada for biosimilar rituximab, but patent litigation may yet prove key to market entry • Source: Shutterstock

More from Biosimilars

More from Products